Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.
Caleb C NgAileen SyEmmett T CunninghamPublished in: Journal of ophthalmic inflammation and infection (2021)
Overall, RTX appears to be both efficacious and well-tolerated as second- or third-line therapy for patients with non-infectious/non-malignant orbital inflammation.